Viatris Targets 5-6% Revenue Growth Through 2030 on Pipeline and Cost Savings
Event summary
- Viatris outlines 2030 targets: 5-6% revenue CAGR, 7-8% adjusted EBITDA CAGR, 9-10% adjusted EPS CAGR.
- Base business expected to deliver 3-4% revenue CAGR, supported by near-term launches and $650M in cost savings.
- $11B available for deployment through 2030, with 50% earmarked for accretive business development.
- Potential blockbusters Selatogrel and Cenerimod could add 1% to revenue CAGR.
- Near-term launches include fast-acting Meloxicam and Low-Dose Estrogen Weekly Patch in the U.S., and Pitolisant and Effexor® for GAD in Japan.
The big picture
Viatris is pivoting from stabilization to growth, leveraging a diversified portfolio and strong cash flow to fund pipeline investments and strategic acquisitions. The company's targets reflect a shift toward higher-margin generics and value-added medicines, aligning with industry trends toward cost-efficient healthcare solutions. Success hinges on executing near-term launches and integrating potential blockbusters into its portfolio.
What we're watching
- Pipeline Execution
- Whether Viatris can successfully launch Selatogrel and Cenerimod to meet growth targets.
- Cost Savings Realization
- The pace at which Viatris can achieve $650M in cost savings and reinvest $250M effectively.
- Capital Deployment
- How Viatris allocates $11B in cash for accretive business development and shareholder returns.
Related topics